VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Fraud Case with Johnson Fistel

SAN DIEGO – Johnson Fistel, PLLP announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) securities between April 1, 2024 and December 16, 2025, inclusive (the “Class Period”). The lawsuit seeks to recover losses for investors under the federal securities laws.

What if I purchased Vistagen Therapeutics securities?

You may also contact James Baker at (619) 814-4471 or jimb@johnsonfistel.com, or Frank J. Johnson, Esq. at fjohnson@johnsonfistel.com to discuss your rights privately.

What is this case about?
According to recently filed class action allegations, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose material facts regarding Vistagen’s business, operations, and prospects. The complaint alleges that defendants provided overwhelmingly positive statements to investors regarding the development and prospects of fasedienol despite the fact that the Company’s Phase 3 PALISADE-3 clinical trial for the acute treatment of social anxiety disorder was beset by materially adverse facts. The complaint further alleges that defendants disseminated false and misleading information and/or concealed material adverse data concerning the PALISADE-3 study’s design, execution, and clinical results. As a result of these omissions and misrepresentations, defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading at all relevant times.

Following disclosures revealing the true state of the PALISADE-3 trial and the clinical prospects of fasedienol, Vistagen’s stock price declined, thereby injuring investors.